Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vertex Pharmaceuticals Incorporated (VRTX : NSDQ)
 
 • Company Description   
Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.

Number of Employees: 3,900

 
 • Price / Volume Information   
Yesterday's Closing Price: $246.72 Daily Weekly Monthly
20 Day Moving Average: 1,789,376 shares
Shares Outstanding: 255.76 (millions)
Market Capitalization: $63,100.11 (millions)
Beta: 0.55
52 Week High: $292.75
52 Week Low: $176.36
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.32% -6.47%
12 Week 7.45% 16.13%
Year To Date 12.35% 33.08%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
50 NORTHERN AVENUE
-
BOSTON,MA 02210
USA
ph: 617-341-6100
fax: 617-576-2109
investorinfo@vrtx.com http://www.vrtx.com
 
 • General Corporate Information   
Officers
Reshma Kewalramani - Chief Executive Officer;President and Director
Jeffrey M. Leiden - Executive Chairman
Charles F. Wagner - Executive Vice President and Chief Financial Offic
Kristen C. Ambrose - Senior Vice President and Chief Accounting Officer
Sangeeta N. Bhatia - Director

Peer Information
Vertex Pharmaceuticals Incorporated (CORR.)
Vertex Pharmaceuticals Incorporated (RSPI)
Vertex Pharmaceuticals Incorporated (CGXP)
Vertex Pharmaceuticals Incorporated (BGEN)
Vertex Pharmaceuticals Incorporated (GTBP)
Vertex Pharmaceuticals Incorporated (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92532F100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 255.76
Most Recent Split Date: 8.00 (2.00:1)
Beta: 0.55
Market Capitalization: $63,100.11 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $3.16 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $12.47 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 10.86% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 19.79
Trailing 12 Months: 19.91
PEG Ratio: 1.82
Price Ratios
Price/Book: 5.79
Price/Cash Flow: 19.53
Price / Sales: 7.94
EPS Growth
vs. Year Ago Period: 24.41%
vs. Previous Quarter: -0.63%
Sales Growth
vs. Year Ago Period: 21.64%
vs. Previous Quarter: 1.20%
ROE
03/31/22 - 32.24
12/31/21 - 32.33
09/30/21 - 31.03
ROA
03/31/22 - 24.39
12/31/21 - 24.26
09/30/21 - 23.18
Current Ratio
03/31/22 - 4.75
12/31/21 - 4.46
09/30/21 - 4.62
Quick Ratio
03/31/22 - 4.60
12/31/21 - 4.30
09/30/21 - 4.45
Operating Margin
03/31/22 - 40.30
12/31/21 - 40.34
09/30/21 - 39.60
Net Margin
03/31/22 - 30.84
12/31/21 - 30.92
09/30/21 - 30.52
Pre-Tax Margin
03/31/22 - 36.04
12/31/21 - 36.05
09/30/21 - 38.54
Book Value
03/31/22 - 42.65
12/31/21 - 39.72
09/30/21 - 37.49
Inventory Turnover
03/31/22 - 2.84
12/31/21 - 2.77
09/30/21 - 2.79
Debt-to-Equity
03/31/22 - 0.05
12/31/21 - 0.05
09/30/21 - 0.05
Debt-to-Capital
03/31/22 - 4.35
12/31/21 - 4.80
09/30/21 - 5.11
 

Powered by Zacks Investment Research ©